期刊文献+

急性心肌梗死患者经皮冠状动脉介入治疗术后慢血流发生与梗死相关动脉病变局部白细胞介素-6水平的关系 被引量:14

Association Between Local Interleukin-6 Levels and Slow Flow in Patients With Acute Myocardial Infarction Undergone PCI
暂未订购
导出
摘要 目的:探讨ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)术后慢血流发生风险与梗死相关动脉管病变局部白细胞介素-6(IL-6)水平的关系。方法:共纳入STEMI行急诊PCI的患者56例,其中男性34例,女性22例,平均年龄(63.5±10.3)岁。PCI术前应用6F Diver CE抽吸导管在导丝支持下,于冠状动脉病变的远端局部取样,采用酶联免疫吸附法测定IL-6水平。结果:共计21例(37.5%)患者发生慢血流。多因素Logistic回归分析表明糖尿病(OR=0.124,95%CI:0.019-0.804,P=0.029)、血栓负荷评分(OR=0.080,95%CI:0.007-0.909,P=0.042)、局部IL-6(OR=0.623,95%CI:0.441-0.881,P=0.007)是慢血流发生的独立危险因素。ROC曲线表明局部IL-6(ROC面积0.824,OR=1.704,95%CI:1.274-2.281,P=0.001;理想阈值:≥11.3pg/ml)对慢血流的发生具有重要预测价值(敏感性为73%,特异性为71%)。结论 :梗死相关动脉病变局部IL-6水平升高与STEMI患者行急诊PCI术后慢血流的发生密切相关。 Objective: We aimed to investigate the association between local interleukin-6 (IL-6) levels at the infarct-related artery and the risk of slow flow after PCI in ST segment elevation myocardial infarction (STEMI) patients treated by successful primary PCI. Methods: 56 eligible STEMI patients (34 male/22 female, mean age: 63.5±10.3 years), undergoing successfully primary PCI, were included in the current study. Blood samples were obtained from the extraction catheter placed distal to the lesion before PCI. Plasma IL-6 levels were determined by immunoassay method. Results: Slow flow was observed in 21 patients (37.5%). Using multiple logistic regression analysis, local IL-6 levels (OR=0.623, 95%CI 0.441-0.881, P=0.007) were found to be a significant risk factor of slow flow together with diabetes mellitus (OR=0.124, 95%CI 0.019-0.804, P=0.029) and thrombus score (OR=0.080, 95%CI 0.007-0.909, P=0.042). Receiver operating characteristic (ROC) curve analysis revealed that local IL-6 (ROC area 0.824, OR=1.704, 95%CI 1.274-2.281, P=0.001 and optimal threshold≥11.3 pg/ml) had a predictive value of slow flow with sensitivity of 73% and specificity of 71%. Conclusion: Our study indicated that inflammatory response as presented by local IL-6 levels was associated with slow flow in patients with STEMI after successfully primary PCI.
出处 《中国循环杂志》 CSCD 北大核心 2014年第3期185-188,共4页 Chinese Circulation Journal
基金 烟台市科技发展计划(批准编号:2013WS221)
关键词 白细胞介素-6 慢血流 炎症反应 急性心肌梗塞 Interleukin-6 Slow flow Inflammation reaction Acute myocardial infarction
  • 相关文献

参考文献22

  • 1Rezkalla SH,Kloner RA.Coronary no-reflow phenomenon:from theexperimental laboratory to the cardiac catheterization laboratory.Catheter Cardiovasc Interv,2008,72:950-957.
  • 2Tanriverdi H,Evrengul H,Kilic ID,et al.Aortic pressures,stiffness and left ventricular function in coronary slow flow phenomenon.Cardiology,2010,116:261-267.
  • 3陈韵岱,王长华.急性心肌梗死经皮冠状动脉介入治疗术后无复流的防治进展[J].中国循环杂志,2010,25(3):165-166. 被引量:42
  • 4Morishima I,Sone T,Okumura K,et al.Angiographic no-reflowphenomenon as a predictor of adverse long-term outcome in patientstreated with percutaneous transluminal coronary angioplasty for firstacute myocardial infarntion.J Am Coll Cardiol,2000,36:1202-1209.
  • 5Resnic FS,Wainstein M,Lee MK,et al.No-reflow is an independentpredictor of death and myocardial infarction after percutaneouscoronary intervention.Am Heart J,2003,145:42-46.
  • 6黎娜,李宪伦.组织因子和组织因子途径抑制物与心肌无复流[J].中国循环杂志,2011,26(4):317-319. 被引量:4
  • 7Pedroza M,Schneider DJ,Karmouty-Quintana H,et al.Interleukin-6 contributes to inflammation and remodeling in a modelof adenosine mediated lung injury.PLoS One,2011,6:e22667.
  • 8Xing Z,Gauldie J,Cox G,et al.IL-6 is an antiinflammatory cytokinerequired for controlling local or systemic acute inflammatoryresponses.J Clin Invest,1998,101:311-320.
  • 9Biasucoi LM,Vitelli A,Liuzzo G,et al.Elevated levels of interleukin-6in unstable angina.Circulation.1996,94:874-877.
  • 10de Boer MJ,Reiher JHC,Suryapranata H,et al.Angiographic findingsand catheterisation lab-oratory events in patients with primarycoronary angioplasty or strep-tokinase therapy for acute myocardialinfarction.Eur Heart J,1995,16:1347-1356.

二级参考文献15

  • 1Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon:from the experimental laboratory to the cardiac catheterization laboratory. Cath- eter cardiovasc interv,2008, 72 (7) :950-957.
  • 2Chong A J, Pohlman TH, Hampton CR, et al. Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg,2003,75 (2) : S649-655.
  • 3Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerot- ic plaque. Blood, 2002,99 (8) :2794-2800.
  • 4Migdalski A, Kotschy M, Jawien A. Tissue factor, tissue factor path- way inhibitor and vascular endothelial growth factor-A in carotid ather- osclerotic plaques. Eur J Vasc Endovasc Surg,2005,30( 1 ) :41-47.
  • 5Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and inter- fering with transfer to CD14. Blood, 1997,89(12) :4268-4274.
  • 6Westrick RJ, Bodary PF, Xu Z, et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation, 2001,103 ( 25 ) :3044-3046.
  • 7Maroney SA, Cooley BC, Ferrel JP, et al. Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arterioscler Thromb Vasc Biol, 2011,31 (4) : 821-826.
  • 8Nakamura Y, Nakamura K, Ohta K, et al. Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor path- way inhibitor after balloon angioplasty. Basic Res Cardiol, 2002,97 (3) :198-205.
  • 9Kopp CW, Holzenbein T, Steiner S, et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activ- ity. Blood, 2004,103 ( 5 ) : 1653-1661.
  • 10Golino P, Ragni M, Cimmino G, ct al. Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagula- tion. Cardiovasc Drug Rev, 2002,20( 1 ) :67-80.

共引文献44

同被引文献171

引证文献14

二级引证文献170

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部